Myriad Genetics' RiskScore improves breast cancer screening recommendations based on individual risk assessments, as shown in a recent study.
Quiver AI Summary
Myriad Genetics, Inc. announced in a press release that a study published in JCO Precision Oncology indicates their RiskScore® tool enhances breast cancer screening by aligning clinician recommendations with patients' individual risk levels. RiskScore, which integrates a polygenic risk score with the Tyrer-Cuzick model, was shown to effectively predict breast cancer risk, leading to increased screening adherence, particularly for patients with a lifetime risk of 20% or more. The study revealed that nearly 20% of patients had differing risk assessments between RiskScore and Tyrer-Cuzick, suggesting that clinicians are increasingly considering polygenic risk scores in their management decisions. Myriad's MyRisk® Hereditary Cancer Test, which assesses multiple genes, provides personalized risk assessments and promotes informed decision-making between patients and healthcare providers regarding breast cancer management.
Potential Positives
- Publication of a real-world study in JCO Precision Oncology demonstrates the efficacy of Myriad's RiskScore® in influencing clinical decision-making for breast cancer screening.
- The study indicates that RiskScore can lead to more personalized and appropriate breast cancer screening for nearly 20% of patients by identifying their individual risk levels.
- Increased utilization of RiskScore results showed a positive impact on patient management, suggesting enhanced collaboration between clinicians and patients in tackling breast cancer risk.
- The findings support Myriad's positioning as a leader in precision medicine, highlighting its commitment to improving patient care through innovative genetic risk assessments.
Potential Negatives
- The study indicates that nearly 20% of patients received a different risk level from RiskScore compared to the established Tyrer-Cuzick model, potentially raising questions about the consistency and reliability of Myriad's testing methodology.
- There is a notable reliance on insurance claims data to determine screening practices post-testing, which could introduce variability and may not fully capture the efficacy of the RiskScore tool.
- The mention of "known and unknown risks and uncertainties" in the forward-looking statements highlights the potential for adverse future impacts on the company's performance and credibility in the market.
FAQ
What is RiskScore® from Myriad Genetics?
RiskScore is a breast cancer risk assessment tool that combines polygenic risk scores with the Tyrer-Cuzick model for individualized risk prediction.
How does RiskScore influence breast cancer screening?
The study shows that RiskScore results help clinicians recommend screening aligned with patients’ specific breast cancer risk levels.
What were the key findings of the study published in JCO Precision Oncology?
The study found that nearly 20% of patients had differing risk levels from Tyrer-Cuzick, affecting their screening recommendations.
Who conducted the recent study on RiskScore?
The study was conducted by researchers including Dr. Allison Kurian from Stanford University School of Medicine and published after the ASCO® Annual Meeting.
What does the MyRisk® Hereditary Cancer Test evaluate?
MyRisk evaluates 48 genes linked to hereditary cancer risk and provides individualized five-year and lifetime breast cancer risk assessments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MYGN Hedge Fund Activity
We have seen 109 institutional investors add shares of $MYGN stock to their portfolio, and 136 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GLENVIEW CAPITAL MANAGEMENT, LLC added 2,895,794 shares (+229.5%) to their portfolio in Q4 2024, for an estimated $39,701,335
- LOOMIS SAYLES & CO L P removed 2,189,601 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $30,019,429
- CAMBER CAPITAL MANAGEMENT LP removed 850,000 shares (-21.5%) from their portfolio in Q4 2024, for an estimated $11,653,500
- MILLENNIUM MANAGEMENT LLC removed 831,315 shares (-16.1%) from their portfolio in Q4 2024, for an estimated $11,397,328
- STATE STREET CORP added 822,263 shares (+17.5%) to their portfolio in Q4 2024, for an estimated $11,273,225
- POINT72 ASSET MANAGEMENT, L.P. removed 715,107 shares (-67.2%) from their portfolio in Q4 2024, for an estimated $9,804,116
- WELLINGTON MANAGEMENT GROUP LLP removed 711,985 shares (-10.6%) from their portfolio in Q4 2024, for an estimated $9,761,314
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MYGN Analyst Ratings
Wall Street analysts have issued reports on $MYGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 03/12/2025
To track analyst ratings and price targets for $MYGN, check out Quiver Quantitative's $MYGN forecast page.
$MYGN Price Targets
Multiple analysts have issued price targets for $MYGN recently. We have seen 2 analysts offer price targets for $MYGN in the last 6 months, with a median target of $16.75.
Here are some recent targets:
- An analyst from Piper Sandler set a target price of $12.5 on 03/12/2025
- Puneet Souda from Leerink Partners set a target price of $21.0 on 12/09/2024
Full Release
SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore ® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment tool integrated into its MyRisk ® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the widely-used Tyrer-Cuzick model to predict five-year and remaining lifetime risk of breast cancer.
The study, “Association of Polygenic-based Breast Cancer Risk Prediction with Patient Management”, was first shared at the 2024 ASCO ® Annual Meeting. Key findings include:
- RiskScore predicted a different risk level than Tyrer-Cuzick for nearly 20% of patients
- Patients with a ≥20% lifetime risk of breast cancer predicted by RiskScore were significantly more likely to have guidelines-aligned screening, such as mammography, breast MRI, and genetic counseling compared to those with <20% lifetime risk.
-
RiskScore results appeared to influence the way clinicians managed patients at increased risk of breast cancer
“Polygenic-based risk predictors are relatively new, and few data have been gathered about how they are being used in clinical practice,” said Allison Kurian, MD, MSc, Professor of Medicine and of Epidemiology and Population Health at Stanford University School of Medicine and senior author on the study. “This study offered reassurance that patients undergo appropriate breast screening after RiskScore testing and suggests that clinicians are considering RiskScore results to make recommendations about risk-based screening for their patients.”
“This real-world, large-scale study represents important progress in understanding how polygenic-based risk scores influence medical management tailored to a patient’s individual risk level,” said Katie Johansen Taber, PhD, VP Clinical Product Research & Partnerships, Myriad Genetics. “With MyRisk with RiskScore, patients may gain insights into their genetically driven risk of developing breast cancer, and clinicians and patients can work together to make informed, proactive decisions on how to best manage that risk.”
About the Study
To conduct this study, patients’ RiskScore results were de-identified and linked with insurance claims data to determine what type of breast cancer screening was undertaken in the one year following genetic testing. Mammography in those under age 40, breast MRI, and genetic counseling, all recommended by guidelines for individuals at increased risk of breast cancer, were compared before and after receiving RiskScore results. The study found that patients with a 20% or greater lifetime risk of breast cancer predicted by either RiskScore or Tyrer-Cuzick were more likely to undergo enhanced screening, while patients with less than 20% lifetime risk did not appear to undertake enhanced screening. These findings suggest that clinicians used the RiskScore results to inform patient management.
About MyRisk
®
Hereditary Cancer Test with RiskScore
®
MyRisk Hereditary Cancer Test with RiskScore
evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients of all ancestries with a five-year and remaining lifetime breast cancer risk assessment individualized to them.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit
www.myriad.com
.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the study represents important progress in understanding how polygenic-based risk scores influence medical management tailored to a patient’s individual risk level, that the study suggests clinicians are considering RiskScore results to make recommendations about risk-based screening for their patients, and that the company believes MyRisk with RiskScore may help patients gain insights into their genetically driven risk of developing breast cancer, supporting informed, proactive decision-making between patients and clinicians about how to best manage that risk. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
[email protected]
Media Contact
Kate Schraml
(224) 875-4493
[email protected]